| 國家衛生研究院 |
2017-10 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Wei, MF;Liou, JM;Wang, HP;Chen, LT;Cheng, AL |
| 臺大學術典藏 |
2020-03-03T03:36:41Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.;Yeh K.-H.;Wu M.-S.;Chung-Wu Lin;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; Kuo S.-H.; Yeh K.-H.; Wu M.-S.; CHUNG-WU LIN; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:17Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Sung-Hsin Kuo;Yeh K.-H.;Wu M.-S.;Lin C.-W.;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; SUNG-HSIN KUO; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-15T03:46:33Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; HSIU-PO WANG; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2022-06-27T07:00:11Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 國立臺灣大學 |
2014 |
First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus
|
Cho, Yung-Tsu; Lee, Fang-Yu; Chu, Chia-Yu; Wang, Li-Fang |
| 臺大學術典藏 |
2019-12-04T08:43:43Z |
First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus
|
Cho Y.-T.;Lee F.-Y.;Chia-Yu Chu;Wang L.-F.; Cho Y.-T.; Lee F.-Y.; CHIA-YU CHU; Wang L.-F. |
| 國立臺灣大學 |
2015 |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Cho, Y. T.; Chu, C. Y.; Wang, L. F.; 王莉芳 |
| 臺大學術典藏 |
2015 |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Cho, Y.T.;Chu, C.Y.;Wang, L.F.; LI-FANG WANG; CHIA-YU CHU |
| 臺大學術典藏 |
2019-12-04T08:43:40Z |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Wang L.F.; Cho Y.T.; CHIA-YU CHU; Cho Y.T.;Chia-Yu Chu;Wang L.F. |
| 國立成功大學 |
2016-08 |
First-Line Disease Modifying Therapies in Preventing Multiple Sclerosis Relapse - A Nationwide Observational Study in Taiwan
|
Chou, Chih-Ho; Lin, Tzu-Chieh; Cheng, Ching-Lan; Yang, Yea-Huei Kao |
| 臺大學術典藏 |
2022-06-27T07:00:23Z |
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study
|
Park K.; CHONG-JEN YU; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. |
| 國家衛生研究院 |
2018-01 |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Yeo, YH;Shiu, SI;Ho, HJ;Zou, B;Lin, JT;Wu, MS;Liou, JM;Wu, CY;Consortium, Taiwan Gastrointestinal Disease and Helicobacter |
| 臺大學術典藏 |
2018-09-10T18:04:31Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis
|
Yeo, Y.H. and Shiu, S.-I. and Ho, H.J. and Zou, B. and Lin, J.-T. and Wu, M.-S. and Liou, J.-M. and Wu, C.-Y.; JYH-MING LIOU; MING-SHIANG WU |
| 臺大學術典藏 |
2020-11-02T02:04:18Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Wu C.-Y.; Liou J.-M.; MING-SHIANG WU; Lin J.-T.; Zou B.; Ho H.J.; Shiu S.-I.; Yeo Y.H. |
| 臺大學術典藏 |
2021-02-02T02:20:59Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Yeo Y.H.; Shiu S.-I.; Ho H.J.; Zou B.; Lin J.-T.; MING-SHIANG WU; Liou J.-M.; Wu C.-Y. |
| 臺大學術典藏 |
2021-05-27T08:20:46Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Yeo Y.H.; Shiu S.-I.; Ho H.J.; Zou B.; Lin J.-T.; Wu M.-S.; JYH-MING LIOU; Wu C.-Y. |
| 國立臺灣大學 |
2013 |
First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
|
Liao, Bin-Chi; Lin, Chia-Chi; Yang, James Chih-Hsin; 林家齊; 楊志新 |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
Liao B.-C;Lin C.-C;Chih-Hsin Yang; Liao B.-C; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:25Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
|
Chih-Hsin Yang;Rajan N;Kim J.S;Puri T;Orlando M;Tsai C.-M;Kang J.H;Srimuninnimit V;Wang X;Boye M; Boye M; Wang X; Srimuninnimit V; Kang J.H; Tsai C.-M; Orlando M; Puri T; Kim J.S; Rajan N; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
Chia-Chi Lin; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.; Srimuninnimit V; Ahn M.-J; Mok T; Kang J.H; Yang J.C.-H |
| 臺大學術典藏 |
2020-05-26T09:26:59Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
CHIH-HSIN YANG; Kang J.H; Mok T; Ahn M.-J; Srimuninnimit V; Lin C.-C; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K. |
